Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Laura Badami

Nurse Practitioner Independence, MO Nurse Practitioner

NPI 1386205961 CMS profile 11206114

19101 E Valley View Pkwy Ste A, Independence, MO 64055

Open in the dashboard

General payments

$12,701

627 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Laura Badami of Independence, MO is reported in the CMS Open Payments database as having received $12,701 across 627 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,030 164
2024 General $4,676 204
2023 General $3,610 204
2022 General $1,125 50
2021 General $261 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Laura Badami
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Laura Badami were reported at $3,030. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Laura Badami Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $261 $135 $40–$426 $132
2022 $1,125 $152 $48–$470 $149
2023 $3,610 $166 $54–$529 $160
2024 $4,676 $173 $55–$556 $164
2025 $3,030 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $3,215 102 payments
  2. AbbVie, Inc. $2,706 156 payments
  3. E.R. Squibb & Sons, L.L.C. $875 50 payments
  4. Lilly USA, LLC $820 62 payments
  5. Pfizer Inc. $673 32 payments
  6. Dermavant Sciences, Inc. $579 52 payments
  7. UCB, Inc. $496 22 payments
  8. Sun Pharmaceutical Industries Inc. $384 16 payments
  9. Regeneron Healthcare Solutions, Inc. $349 12 payments
  10. Novartis Pharmaceuticals Corporation $344 15 payments
  11. Other $2,259 108 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $11,096 616 payments
  2. Consulting Fee $850 1 payment
  3. Education $724 9 payments
  4. Travel and Lodging $31 1 payment
Products named General payments · program years 2021–2025
  1. TREMFYA $3,279 106 payments
  2. RINVOQ $1,626 88 payments
  3. SKYRIZI $900 56 payments
  4. SOTYKTU $869 49 payments
  5. VTAMA $673 60 payments
  6. TALTZ $659 52 payments
  7. LITFULO $534 26 payments
  8. DUPIXENT $485 17 payments
  9. CIBINQO $452 29 payments
  10. OLUMIANT $422 30 payments
  11. Other $4,191 210 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

1,325

Median for Nurse Practitioner: 389

Drug cost

$461,275

Median for Nurse Practitioner: $21,885

Branded share of claims

3.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 23 $351,981
Dupixent Pen Dupilumab Brand 20 $83,198
Ketoconazole Generic 360 $5,336
Clobetasol Propionate Generic 84 $3,697
Doxycycline Hyclate Generic 116 $3,082
Betamethasone Dipropionate Generic 59 $2,986
Finasteride Generic 156 $1,548
Calcipotriene Generic 12 $1,438
Minoxidil Generic 174 $1,357
Tretinoin Generic 16 $1,330

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$82,844

Of which drugs: $2,393

Medicare patients

529

Average age 74

Services billed

2,449

335 women, 194 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 47%
Diabetes 30%
Ischemic heart disease 27%
Chronic kidney disease 22%
Osteoporosis 19%
Depression 18%
COPD 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 62 337 $225

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $1,482
  • Janssen Pharmaceuticals, Inc $64
$1,546 — —
RINVOQ
  • AbbVie, Inc. $459
$459 — —
VTAMA
  • Dermavant Sciences, Inc. $396
$396 — —
SKYRIZI
  • AbbVie, Inc. $375
$375 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $330
$330 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

627 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record